Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Neoplasms 10Melanoma 9Lung Neoplasms 8Breast Neoplasms 8Multiple Myeloma 7Leukemia, Myeloid, Acute 7Prostatic Neoplasms 6Pancreatic Neoplasms 6Ovarian Neoplasms 5Neoplasm Metastasis 5Colorectal Neoplasms 5Brain Neoplasms 5Myelodysplastic Syndromes 4Lymphoma, Non-Hodgkin 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Endometrial Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Carcinoma, Transitional Cell 3Carcinoma, Renal Cell 3Thyroid Neoplasms 2

Interventions

enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Bulbo-Spinal Atrophy, X-Linked × 30 days × Clear all
NCT03437941 2026-05-15

Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Corcept Therapeutics

Phase 1/2 Terminated
39 enrolled 43 charts
Genitourinary

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon âš¡